2-庚基乙酰乙酸乙酯 | 40778-30-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 2-庚基乙酰乙酸乙酯
• 中文别名: 2-乙酰基壬酸乙酯
• 英文名称: ethyl 2-acetylnonanoate
• 英文别名: α-n-Heptyl-acetessigsaeureaethylester；2-Heptyl-acetessigsaeure-ethylester；2-n-Heptylacetessigester；α-Heptyl-acetessigsaeure-ethylester；2-heptyl-acetoacetic acid ethyl ester；2-Heptyl-acetessigsaeure-aethylester；ethyl 2-acetylnonan-1-oate；ethyl 2-heptylacetoacetate
• CAS: 40778-30-1
• 化学式: C₁₃H₂₄O₃
• 分子量: 228.332
• InChiKey: QPFZUKLNMHJNCE-UHFFFAOYSA-N

物化性质

• 沸点：
  162-163 °C(Press: 18 Torr)
• 密度：
  0.9291 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  2-庚基乙酰乙酸乙酯 在 potassium carbonate 作用下， 生成 2-癸酮
  参考文献：
  名称：

  Jourdan, Justus Liebigs Annalen der Chemie, 1880, vol. 200, p. 102

  摘要：

  DOI：
• 作为产物：
  描述：

  2-乙酰基壬-2-烯酸乙酯 在 Pd/SrCO₃ 、 乙醇 作用下， 生成 2-庚基乙酰乙酸乙酯
  参考文献：
  名称：

  Stephen; Tonkin; Walker, Journal of the Chemical Society, 1947, p. 1039

  摘要：

  DOI：

文献信息

• The influence of pharmacy staff in non-prescription medicine sales
  作者：Lynne Emmerton、John Shaw

  DOI：10.1111/j.2042-7174.2002.tb00594.x

  日期：2011.2.22

  To monitor sales of non-prescription medicines from pharmacies in New Zealand, and report specifically on the involvement and influence of pharmacy staff.

  Purchasers of non-prescription medicines were interviewed in-store immediately following their purchase. A brief structured questionnaire was used to record current and previous medicine purchases, influences on first-time purchases and demographic descriptors. Non-intrusive observational data were collected where possible in the case of non-response.

  Data were collected in 12 pharmacies in New Zealand during winter 1999. Pharmacies were selected to approximate the population distribution, and had a range of sizes and practice settings. Interviews took place over five consecutive days in each pharmacy.

  The recorded purchases totalled 2,597 (69–397 per pharmacy), representing 71.2 per cent of observed medicine sales. Some two-thirds of all medicines had been purchased on a previous occasion. In two-thirds of sales, pharmacy assistants provided consultation with no pharmacist input. Two-thirds of purchases were for a pre-determined brand, and consultation occurred less frequently when these were self-selected from the shelf. Involvement by pharmacy staff was particularly noted when a change of brand occurred, when a desired brand was sought from staff, and when no particular brand was sought. For first-time purchases, the influence of pharmacy staff (62.2 per cent of all influences recorded) dominated that of family and friends (15.5 per cent).

  Pharmacy staff play an active role in non-prescription medicine sales, despite most purchases apparently being straightforward in nature. Guidelines for appropriate product selection and advice are particularly important when training pharmacy assistants.

  摘要 目标 监测新西兰药房非处方药品的销售情况，特别关注药房工作人员的参与和影响。 方法 在购买非处方药品后，立即在店内对购买者进行采访。使用简短的结构化问卷记录当前和以前的药品购买情况，首次购买的影响因素以及人口统计描述符。在无响应情况下，尽可能收集非侵入式的观察数据。 背景 1999年冬季，在新西兰的12家药房收集数据。选择药房以接近人口分布，并具有各种规模和实践设置。每家药房连续五天进行采访。 主要发现 记录的购买总数为2,597（每家药房69-397个），占观察到的药品销售的71.2％。大约三分之二的药品曾经被购买过。在三分之二的销售中，药房助理提供咨询，没有药剂师的参与。三分之二的购买是为预定品牌，当这些品牌从货架上自选时，咨询发生的频率较低。当更换品牌时，寻求员工提供所需品牌以及不寻求特定品牌时，特别注意药房工作人员的参与。对于首次购买，药房工作人员的影响（记录的所有影响中占62.2％）主导了家人和朋友的影响（占15.5％）。 结论 尽管大多数购买显然是简单的，但药房工作人员在非处方药销售中发挥着积极作用。在培训药房助理时，适当产品选择和建议的准则尤为重要。
• COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY
  申请人：Riscoe Michael K.

  公开号：US20120115904A1

  公开（公告）日：2012-05-10

  Compounds of formula I: or formula II: or a pharmaceutically acceptable salt of formula I or formula II, wherein: R 1 is H, hydroxyl, alkoxy, acyl, alkyl, cycloalkyl, aryl, or heteroaryl; R 2 is methyl or haloalkyl; R 4 is hydroxyl, carbonyloxy, or carbonyldioxy; and R 3 is aliphatic, aryl, aralkyl, or alkylaryl; and R 5 , R 6 , R 7 and R 8 are each individually H, halogen, alkoxy, alkyl, haloalkyl, aryl, nitro, cyano, amino, amido, acyl, carboxyl, substituted carboxyl, or —SO 2 R 10 , wherein R 10 is H, alkyl, amino or haloalkyl; provided that in formula I, R 5 and R are not both H or R 6 is not H or methoxy; and in formula II that if R 4 is carbonyldioxy then R 7 is not methoxy.

  化合物的化学式为I式：或II式：或I式或II式的药学上可接受的盐，其中：R1为氢、羟基、烷氧基、酰基、烷基、环烷基、芳基或杂环芳基；R2为甲基或卤代烷基；R4为羟基、羰酸酯基或羰基二氧基；R3为脂肪基、芳基、芳基烷基或烷基芳基；以及R5、R6、R7和R8分别为氢、卤素、烷氧基、烷基、卤代烷基、芳基、硝基、氰基、氨基、酰基、羧基、取代羧基或-SO2R10，其中R10为氢、烷基、氨基或卤代烷基；但在I式中，R5和R6不能同时为氢或R6不为氢或甲氧基；在II式中，如果R4为羰基二氧基，则R7不为甲氧基。
• 2-Substituted amino-4(1H)-pyrimidone derivatives, their production, and medical compositions containing them
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0186275A2

  公开（公告）日：1986-07-02

  A 2-substituted amino-4 (1H)-pyrimidone derivative shown by the general formula wherein R' and R2, which may be the same or different, each represents a hydrogen atom or a lower alkyl group; R3 represents an alkyl group, an alkenyl group, an alkynyl group, a halogen-substituted alkyl group, a halogen-substituted alkenyl group, a halogen-substituted alkynyl group, or an alkyl group interrupted by an oxygen atom or a sulfur atom; R4 represents a hydrogen atom or a lower alkyl group; m is an integer of 1 or 3 and n is an integer of 2 or 4 (with said R4 being a lower alkyl group when R' and R2 are hydrogen atoms, R3 is an alkyl group, m is 2 and n is 3) or an acid addition salt thereof. The compounds of this invention have both histamine H2-receptor antagonist activity and gastric cytoprotective activity and are very useful as drugs for gastric diseases.

  通式如下的 2-取代氨基-4(1H)-嘧啶酮衍生物 其中 R'和 R2（可以相同或不同）各自代表氢原子或低级烷基；R3 代表烷基、烯基、炔基、卤素取代的烷基、卤素取代的烯基、卤素取代的炔基、或被氧原子或硫原子打断的烷基；R4 代表氢原子或低级烷基；m 为 1 或 3 的整数，n 为 2 或 4 的整数（当 R' 和 R2 为氢原子，R3 为烷基，m 为 2，n 为 3 时，所述 R4 为低级烷基）或其酸加成盐。 本发明的化合物同时具有组胺 H2 受体拮抗剂活性和胃细胞保护活性，作为治疗胃病的药物非常有用。
• METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP0937703A1

  公开（公告）日：1999-08-25

  The present invention is directed to a method for purifying pyruvic acid compounds, which method comprises reacting a pyruvic acid compound of general formula (I): wherein R1 is an optionally substituted lower alkyl group, a lower alkenyl group, a lower alkynyl group, a cycloalkyl group, an aryl group, or a heterocyclic group, and R2 is a lower alkyl group, with a bisulfite of general formula (II):         MHSO3     (II) wherein M is NH4 or an alkali metal, to give a bisulfite adduct of the pyruvic acid compound and then decomposing the adduct with an acid. According to the present invention, pyruvic acid compounds can be purified by simple and easy procedures without using purification techniques such as distillation or column chromatography, and the above method is advantageous as a process for the production on an industrial scale.

  本发明涉及一种纯化丙酮酸化合物的方法，该方法包括使通式(I)的丙酮酸化合物反应： 其中 R1 是任选取代的低级烷基、低级烯基、低级炔基、环烷基、芳基或杂环基，R2 是低级烷基，与通式（II）的亚硫酸氢盐反应： MHSO3 (II) 其中 M 为 NH4 或碱金属，以得到丙酮酸化合物的亚硫酸氢盐加合物，然后用酸分解该加合物。根据本发明，丙酮酸化合物可以通过简单易行的程序进行纯化，而无需使用蒸馏或柱层析等纯化技术，上述方法作为一种工业规模的生产工艺是非常有利的。
• Use of Plasma Exchange and Heparin During Cardiopulmonary Bypass for a Patient with Heparin Induced Thrombocytopenia: A Case Report
  作者：Michio Kajitani、Miguel Aguinaga、Charles E. Johnson、Margie A. Scott、Tamim Antakli

  DOI：10.1111/j.1540-8191.2001.tb00527.x

  日期：2001.7

  Patients with documented history of heparin-induced thrombocytopenia (HIT) pose a difficult problem during surgery using cardiopulmonary bypass (CPB). Several alternatives to heparin exist, but these products either are not approved for use in the United States or have more side effects than heparin. We report on a patient with documented heparin-induced antibody and left main coronary artery disease who underwent uneventful coronary artery bypass surgery and recovery by using preoperative plasmaphresis and limited use of porcine intestinal heparin during CPB.